Cytokinetics (CYTK) Stifel 2026 Healthcare Conference 2026 summary

Launch performance and adoption

• Revenue rose 76% QoQ and patient dispenses exceeded 2,800, versus 1,500 in Q2; the CMI market grew 45% YoY.

• New-to-brand share reached 45% after eight months on market; management expects continued growth but described share gains as harder as adoption expands.

• More than 3,000 HCPs are REMS-certified; two-thirds write prescriptions or are affiliated with a writer, and average productivity is four patients per prescriber, seven among concentrated users.

• Community cardiologists new to the class are beginning to prescribe; average productivity in this group has increased from one patient to two.

• Medicare coverage is at parity with CAMZYOS for 90% of covered lives; commercial coverage rose to 60% from 50% a quarter earlier, with further improvement expected through 2027.

Aficamten use and differentiation

• Prescribers use the 2–8-week titration and monitoring window; typical titration currently takes 4–6 weeks, with some patient-dependent faster dose increases.

• Management cited flexible dosing, rapid efficacy, a shorter half-life, and a less burdensome REMS as differentiators; maintenance monitoring can move to every six months after an appropriate initial response.

• CAMZYOS switches have remained in the mid-single digits through the first three launch quarters; switching is not a primary focus.

Non-obstructive HCM and pipeline

• MAPLE-HCM sNDA was expected the following week, with an nHCM submission planned by year-end and European activity expected in early 2027.

• ACACIA-HCM showed a treatment effect management described as consistent across prespecified subgroups; the proposed nHCM approach is to start symptomatic patients at a low dose and titrate to the maximum tolerated dose, then assess how they feel.

• In ACACIA-HCM, 12 patients developed heart failure during titration versus three placebo patients later in the study; management attributed the difference to computer-driven titration and said physician-guided FOREST-HCM titration avoided that risk in the comparable period.

• If approved, nHCM labeling and REMS may seek to mirror oHCM practice, using ejection fraction rather than LVOT gradient for titration; a similar launch cadence is expected, balanced by continued nHCM disease education.

• CAMELLIA-HCM in Japan completed its main treatment period; ACACIA-HCM data were presented at ESC.